Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.

ABSTRACT:

Background

Recent therapeutic advances and screening technologies have improved survival among patients with lung cancer, who are now at high risk of developing second primary lung cancer (SPLC). Recently, an SPLC risk-prediction model (called SPLC-RAT) was developed and validated using data from population-based epidemiological cohorts and clinical trials, but real-world validation has been lacking. The predictive performance of SPLC-RAT was evaluated in a hospital-based cohort of lung cancer survivors.

Methods

The authors analyzed data from 8448 ever-smoking patients diagnosed with initial primary lung cancer (IPLC) in 1997-2006 at Mayo Clinic, with each patient followed for SPLC through 2018. The predictive performance of SPLC-RAT and further explored the potential of imp

SUBMITTER: Choi E 

PROVIDER: S-EPMC10922086 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature